US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
US4169888A
(en)
|
1977-10-17 |
1979-10-02 |
The Upjohn Company |
Composition of matter and process
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
EP0028683A1
(fr)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotique C-15003 PHO et sa préparation
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
US4364935A
(en)
|
1979-12-04 |
1982-12-21 |
Ortho Pharmaceutical Corporation |
Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
|
WO1982001188A1
(fr)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
Composes 4,5-deoxymaytansinoide et leur procede de preparation
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
US4970198A
(en)
|
1985-10-17 |
1990-11-13 |
American Cyanamid Company |
Antitumor antibiotics (LL-E33288 complex)
|
DE3675588D1
(de)
|
1985-06-19 |
1990-12-20 |
Ajinomoto Kk |
Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
|
AU597574B2
(en)
|
1986-03-07 |
1990-06-07 |
Massachusetts Institute Of Technology |
Method for enhancing glycoprotein stability
|
EP0271581B1
(fr)
|
1986-04-17 |
1993-01-13 |
Kyowa Hakko Kogyo Co., Ltd. |
Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5053394A
(en)
|
1988-09-21 |
1991-10-01 |
American Cyanamid Company |
Targeted forms of methyltrithio antitumor agents
|
WO1989006692A1
(fr)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Noble hydrazonic history of anthracycline and methods for their preparation
|
US5084468A
(en)
|
1988-08-11 |
1992-01-28 |
Kyowa Hakko Kogyo Co., Ltd. |
Dc-88a derivatives
|
JP2598116B2
(ja)
|
1988-12-28 |
1997-04-09 |
協和醗酵工業株式会社 |
新規物質dc113
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5187186A
(en)
|
1989-07-03 |
1993-02-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Pyrroloindole derivatives
|
JP2510335B2
(ja)
|
1989-07-03 |
1996-06-26 |
協和醗酵工業株式会社 |
Dc―88a誘導体
|
CA2026147C
(fr)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
AU652936B2
(en)
|
1990-05-07 |
1994-09-15 |
Scripps Clinic And Research Foundation |
Intermediates in the formation of the calicheamicin and esperamicin oligosaccharides
|
US5968509A
(en)
|
1990-10-05 |
1999-10-19 |
Btp International Limited |
Antibodies with binding affinity for the CD3 antigen
|
EP1362868A3
(fr)
|
1991-03-06 |
2004-02-11 |
MERCK PATENT GmbH |
Anticorps monoclonaux humanisés et chimériques se liant au récepteur du facteur de croissance épidermique (EGF-R)
|
DE122004000008I1
(de)
|
1991-06-14 |
2005-06-09 |
Genentech Inc |
Humanisierter Heregulin Antikörper.
|
WO1994004679A1
(fr)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Procede pour fabriquer des anticorps humanises
|
US5264586A
(en)
|
1991-07-17 |
1993-11-23 |
The Scripps Research Institute |
Analogs of calicheamicin gamma1I, method of making and using the same
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
DK0563475T3
(da)
|
1992-03-25 |
2000-09-18 |
Immunogen Inc |
Konjugater af cellebindende midler og derivater af CC-1065
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
US6329507B1
(en)
|
1992-08-21 |
2001-12-11 |
The Dow Chemical Company |
Dimer and multimer forms of single chain polypeptides
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
EP0672142B1
(fr)
|
1992-12-04 |
2001-02-28 |
Medical Research Council |
Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation
|
EP0628078B1
(fr)
|
1992-12-11 |
1999-12-08 |
The Dow Chemical Company |
Anticorps monocatenaires multivalents
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
DE69434136T2
(de)
|
1993-10-01 |
2005-12-01 |
Teikoku Hormone Mfg. Co., Ltd. |
Dolastatin-derivate
|
GB9401182D0
(en)
|
1994-01-21 |
1994-03-16 |
Inst Of Cancer The Research |
Antibodies to EGF receptor and their antitumour effect
|
CA2165819C
(fr)
|
1994-04-22 |
2005-12-27 |
Nobuyoshi Amishiro |
Derives de dc-89
|
JPH07309761A
(ja)
|
1994-05-20 |
1995-11-28 |
Kyowa Hakko Kogyo Co Ltd |
デュオカルマイシン誘導体の安定化法
|
US5945311A
(en)
|
1994-06-03 |
1999-08-31 |
GSF--Forschungszentrumfur Umweltund Gesundheit |
Method for producing heterologous bi-specific antibodies
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5550246A
(en)
|
1994-09-07 |
1996-08-27 |
The Scripps Research Institute |
Calicheamicin mimics
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
AU6267896A
(en)
|
1995-06-07 |
1996-12-30 |
Imclone Systems Incorporated |
Antibody and antibody fragments for inhibiting the growth oftumors
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US7696338B2
(en)
|
1995-10-30 |
2010-04-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunotoxin fusion proteins and means for expression thereof
|
ES2195036T3
(es)
|
1995-12-22 |
2003-12-01 |
Bristol Myers Squibb Co |
Conectores de hidrazona ramificados.
|
US6177078B1
(en)
|
1995-12-29 |
2001-01-23 |
Medvet Science Pty Limited |
Monoclonal antibody antagonists to IL-3
|
EP0915987A2
(fr)
|
1997-04-21 |
1999-05-19 |
Donlar Corporation |
ACIDE POLY-$g(a)-L-ASPARTIQUE, ACIDE-POLY-$g(a)-L-GLUTAMIQUE ET COPOLYMERES DE L-ASP ET L-GLU, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION
|
CA2288600C
(fr)
|
1997-05-02 |
2010-06-01 |
Genentech, Inc. |
Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
DK1049787T3
(da)
|
1998-01-23 |
2005-04-04 |
Vlaams Interuniv Inst Biotech |
Antistofderivater med flere anvendelsesmuligheder
|
EP2261229A3
(fr)
|
1998-04-20 |
2011-03-23 |
GlycArt Biotechnology AG |
Modification par glycosylation d'anticorps aux fins d'amélioration de la cytotoxicité cellulaire dépendant des anticorps
|
ES2203141T3
(es)
|
1998-04-21 |
2004-04-01 |
Micromet Ag |
Polipeptidos cd19 x cd3 especificos y su utilizacion.
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
CA2335364C
(fr)
|
1998-06-22 |
2010-05-04 |
Immunomedics, Inc. |
Utilisation d'anticorps bi-specifiques pour diagnostic et therapie de pre-ciblage
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
US6723538B2
(en)
|
1999-03-11 |
2004-04-20 |
Micromet Ag |
Bispecific antibody and chemokine receptor constructs
|
EP2270148A3
(fr)
|
1999-04-09 |
2011-06-08 |
Kyowa Hakko Kirin Co., Ltd. |
Méthode de régulation de l'activité d'une molécule immunologiquement fonctionnelle
|
US6939545B2
(en)
|
1999-04-28 |
2005-09-06 |
Genetics Institute, Llc |
Composition and method for treating inflammatory disorders
|
CA2385528C
(fr)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
|
US7303749B1
(en)
|
1999-10-01 |
2007-12-04 |
Immunogen Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
AU7950400A
(en)
|
1999-10-19 |
2001-04-30 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for producing polypeptide
|
US6716410B1
(en)
|
1999-10-26 |
2004-04-06 |
The Regents Of The University Of California |
Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
|
YU63302A
(sh)
|
2000-02-25 |
2005-09-19 |
The Government Of The Un.Stat. |
Anti-egfrv iii scfvs sa pojačanom citotoksičnošću i povećanim prinosom, imunotoksini na bazi istog i metodi za upotrebu na bazi istog
|
US7449443B2
(en)
|
2000-03-23 |
2008-11-11 |
California Institute Of Technology |
Method for stabilization of proteins using non-natural amino acids
|
US20010035606A1
(en)
|
2000-03-28 |
2001-11-01 |
Schoen Alan H. |
Set of blocks for packing a cube
|
EP1278778A2
(fr)
|
2000-05-03 |
2003-01-29 |
Amgen Inc., |
Peptides modifies comprenant un domaine fc utilises comme agents therapeutiques
|
BR0110927A
(pt)
|
2000-05-19 |
2003-03-11 |
Scancell Ltd |
Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
|
WO2001090192A2
(fr)
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Proteines bispecifiques de liaison a l'antigene du type immunoglobulines, et procede de production correspondant
|
US6586207B2
(en)
|
2000-05-26 |
2003-07-01 |
California Institute Of Technology |
Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
|
CA2417185A1
(fr)
|
2000-07-25 |
2002-01-31 |
Shui-On Leung |
Proteine de liaison cible multivalente
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
DE10043437A1
(de)
|
2000-09-04 |
2002-03-28 |
Horst Lindhofer |
Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
|
ES2639222T5
(es)
|
2000-10-06 |
2023-11-24 |
Kyowa Kirin Co Ltd |
Células que producen unas composiciones de anticuerpo
|
CA2424977C
(fr)
|
2000-10-06 |
2008-03-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de purification d'un anticorps
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20020147312A1
(en)
|
2001-02-02 |
2002-10-10 |
O'keefe Theresa |
Hybrid antibodies and uses thereof
|
EP1243276A1
(fr)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Prodrogues activables à séparateurs allongés et multiples
|
JP2005500018A
(ja)
|
2001-04-02 |
2005-01-06 |
アイデック ファーマスーティカルズ コーポレイション |
GnTIIIと同時発現する組換え抗体
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
CN101671335A
(zh)
|
2001-05-31 |
2010-03-17 |
梅达莱克斯公司 |
细胞毒素、其有用的前体药物、连接基团和稳定剂
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
IL159225A0
(en)
|
2001-06-13 |
2004-06-01 |
Genmab As |
Human monoclonal antibodies to epidermal growth factor receptor (egfr)
|
US20040242851A1
(en)
|
2001-06-26 |
2004-12-02 |
Zhenping Zhu |
Bispecific antibodies that bind to vegf receptors
|
US6513428B1
(en)
|
2001-07-23 |
2003-02-04 |
Heidelberger Druckmaschinen Ag |
Device and method for attaching a printing web to a webbing sail and device and method for webbing-up a printing machine
|
HUP0600342A3
(en)
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
EP1490677A4
(fr)
|
2002-02-27 |
2006-01-18 |
California Inst Of Techn |
Procede informatique de conception d'enzymes pour l'incorporation d'analogues d'acides amines dans des proteines
|
US7657380B2
(en)
|
2003-12-04 |
2010-02-02 |
Xencor, Inc. |
Methods of generating variant antibodies with increased host string content
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20080219974A1
(en)
|
2002-03-01 |
2008-09-11 |
Bernett Matthew J |
Optimized antibodies that target hm1.24
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
CA2484000A1
(fr)
|
2002-05-24 |
2003-12-04 |
Schering Corporation |
Anticorps anti-igfr humain neutralisant
|
WO2005056606A2
(fr)
|
2003-12-03 |
2005-06-23 |
Xencor, Inc |
Proteines optimisees qui ciblent le recepteur du facteur de croissance epidermique
|
ES2544527T3
(es)
|
2002-07-31 |
2015-09-01 |
Seattle Genetics, Inc. |
Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
EP1560599A1
(fr)
|
2002-11-14 |
2005-08-10 |
Syntarga B.V. |
Promedicaments con us en tant qu'espaceurs de liberation multiple a elimination automatique
|
AU2003295471B2
(en)
|
2002-11-15 |
2011-08-25 |
Genmab A/S |
Human monoclonal antibodies against CD25
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
BRPI0410748B8
(pt)
|
2003-05-20 |
2021-05-25 |
Immunogen Inc |
compostos de maitansinóides, suas composições farmacêuticas, métodos de esterificação de maitansinóides, bem como métodos para a sua produção, e conjugado de maitansinóide-agente de ligação celular
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
AU2004242846A1
(en)
|
2003-05-31 |
2004-12-09 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
|
RU2005137325A
(ru)
|
2003-05-31 |
2006-09-10 |
Микромет Аг (De) |
Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам
|
US7888134B2
(en)
|
2003-06-05 |
2011-02-15 |
Oakland University |
Immunosensors: scFv-linker design for surface immobilization
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
US20150071948A1
(en)
|
2003-09-26 |
2015-03-12 |
Gregory Alan Lazar |
Novel immunoglobulin variants
|
SG143252A1
(en)
|
2003-10-09 |
2008-06-27 |
Ambrx Inc |
Polymer derivatives
|
US20050176028A1
(en)
|
2003-10-16 |
2005-08-11 |
Robert Hofmeister |
Deimmunized binding molecules to CD3
|
SG149815A1
(en)
|
2003-11-06 |
2009-02-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
EP2275448A3
(fr)
|
2003-12-19 |
2013-02-06 |
Genentech, Inc. |
Fragments d'anticorps monovalent et leur utilisation thérapeutique
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
NZ586034A
(en)
|
2004-02-02 |
2011-10-28 |
Ambrx Inc |
Modified human growth hormone polypeptides and their uses
|
BRPI0510909A2
(pt)
|
2004-05-19 |
2008-12-16 |
Medarex Inc |
composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
|
US7691962B2
(en)
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
SG188175A1
(en)
|
2004-06-03 |
2013-03-28 |
Novimmune Sa |
Anti-cd3 antibodies and methods of use thereof
|
US20060018897A1
(en)
|
2004-06-28 |
2006-01-26 |
Transtarget Inc. |
Bispecific antibodies
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
CA2577405A1
(fr)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Anticorps anti-recepteur fcgammariib et correspondantes
|
CN101065151B
(zh)
|
2004-09-23 |
2014-12-10 |
健泰科生物技术公司 |
半胱氨酸改造的抗体和偶联物
|
DK1797127T3
(en)
|
2004-09-24 |
2017-10-02 |
Amgen Inc |
Modified Fc molecules
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US8066989B2
(en)
|
2004-11-30 |
2011-11-29 |
Trion Pharma Gmbh |
Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
|
JP4937138B2
(ja)
|
2005-01-05 |
2012-05-23 |
エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
相補性決定領域とは異なる分子の領域に設計された結合性を持つ合成免疫グロブリンドメイン
|
WO2006075668A1
(fr)
|
2005-01-12 |
2006-07-20 |
Kirin Beer Kabushiki Kaisha |
Anticorps igg1 et igg 3 humains stabilisés
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
EP3260465A1
(fr)
|
2005-06-07 |
2017-12-27 |
ESBATech, an Alcon Biomedical Research Unit LLC |
Anticorps stables et solubles inhibant le tnf-alpha
|
EP1910575B1
(fr)
|
2005-07-01 |
2014-12-10 |
Dako Denmark A/S |
Procede de detection par immunohistochimie
|
JP2009500344A
(ja)
|
2005-07-01 |
2009-01-08 |
メディミューン,エルエルシー |
マルチドメインタンパク質治療薬を製造するための統合的手法
|
CN101267836A
(zh)
|
2005-07-25 |
2008-09-17 |
特鲁比昂药品公司 |
单剂量cd20特异性结合分子的用途
|
SI2298815T1
(sl)
|
2005-07-25 |
2015-08-31 |
Emergent Product Development Seattle, Llc |
Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20
|
EP1909846B1
(fr)
|
2005-08-05 |
2018-12-26 |
Syntarga B.V. |
Bras de liaison detachables contenant du triazole, conjugues de ceux-ci et procedes de preparation
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
ES2856451T3
(es)
|
2005-10-11 |
2021-09-27 |
Amgen Res Munich Gmbh |
Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
|
JP5362359B2
(ja)
|
2005-10-12 |
2013-12-11 |
モルフォシス アーゲー |
ヒトCD38に特異的な完全ヒトHuCALGOLD由来の治療抗体の生成とプロファイリング
|
JP2009511067A
(ja)
|
2005-10-14 |
2009-03-19 |
メディミューン,エルエルシー |
抗体ライブラリーの細胞提示
|
WO2007047829A2
(fr)
|
2005-10-19 |
2007-04-26 |
Laboratoires Serono S.A. |
Nouvelles protéines hétérodimères et utilisations de celles-ci
|
AR056142A1
(es)
|
2005-10-21 |
2007-09-19 |
Amgen Inc |
Metodos para generar el anticuerpo igg monovalente
|
WO2007059404A2
(fr)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Composes et conjugues cytotoxiques
|
AU2006318580A1
(en)
|
2005-11-21 |
2007-05-31 |
Merck Serono Sa |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
CA2633713A1
(fr)
|
2005-12-21 |
2007-06-28 |
Micromet Ag |
Molecules epha2 bite et leur utilisation
|
CA2641899A1
(fr)
|
2006-02-02 |
2007-08-09 |
Syntarga B.V. |
Analogues de cc-1065 hydrosolubles et leurs conjugues
|
EP1820513A1
(fr)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction des cellules tumorales exprimant à un niveau bas ou moyen des antigènes cibles associés aux tumeurs, par des anticorps trifonctionels bispécifiques
|
EP1829895A1
(fr)
|
2006-03-03 |
2007-09-05 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Molécule bispécifique anti-TLR9 et anti-CD32 contenant un épitope de lymphocyte T pour le traitement des allergies
|
CA2646508A1
(fr)
|
2006-03-17 |
2007-09-27 |
Biogen Idec Ma Inc. |
Compositions polypeptidiques stabilisees
|
PL1999154T3
(pl)
|
2006-03-24 |
2013-03-29 |
Merck Patent Gmbh |
Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
|
EP4342995A2
(fr)
|
2006-03-31 |
2024-03-27 |
Chugai Seiyaku Kabushiki Kaisha |
Procédés de régulation de la pharmacocinétique sanguine d'anticorps
|
JP5144499B2
(ja)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
EP2007423A2
(fr)
|
2006-04-05 |
2008-12-31 |
Pfizer Products Incorporated |
Polythérapie à base d'un anticorps anti-ctla4
|
JP2009541275A
(ja)
|
2006-06-22 |
2009-11-26 |
ノボ・ノルデイスク・エー/エス |
二重特異性抗体の生産
|
AT503861B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von t-zell-rezeptoren
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
DK2069558T3
(da)
|
2006-10-02 |
2013-08-05 |
Sea Lane Biotechnologies Llc |
Design og konstruktion af forskelligartede syntektiske peptid- og polypeptidbiblioteker
|
CA2680237C
(fr)
|
2007-03-27 |
2018-11-06 |
Sea Lane Biotechnologies, Llc |
Constructions et bibliotheques comprenant des sequences de chaines legeres de substitution d'anticorps
|
EP1975178A1
(fr)
|
2007-03-30 |
2008-10-01 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Anticorps modulaire transcytotique
|
US20100183615A1
(en)
|
2007-04-03 |
2010-07-22 |
Micromet Ag |
Cross-species-specific bispecific binders
|
EP4059964A1
(fr)
|
2007-04-03 |
2022-09-21 |
Amgen Research (Munich) GmbH |
Domaine de liaison inter-especes
|
WO2008124858A2
(fr)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Récepteur ciblé
|
CA2687117A1
(fr)
|
2007-05-14 |
2008-11-27 |
Biogen Idec Ma Inc. |
Regions fc simple chaine, polypeptides de liaison comportant de telles regions, et procedes correspondants
|
EP2176298B1
(fr)
|
2007-05-30 |
2017-11-15 |
Xencor, Inc. |
Procédés et compositions permettant l'inhibition de cellules d'expression du cd32b
|
AU2008255352B2
(en)
|
2007-05-31 |
2014-05-22 |
Genmab A/S |
Stable IgG4 antibodies
|
CN101842389A
(zh)
|
2007-06-12 |
2010-09-22 |
惠氏有限责任公司 |
抗cd20治疗组合物和方法
|
WO2009000006A1
(fr)
|
2007-06-26 |
2008-12-31 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. |
Présentation d'agents de liaison
|
WO2009017394A1
(fr)
|
2007-08-01 |
2009-02-05 |
Syntarga B.V. |
Analogues cc-1065 substitués et leurs conjugués
|
EP2187971A2
(fr)
|
2007-08-01 |
2010-05-26 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Immunotoxine de la toxine diphtérique d'un dianticorps de repliement et ses procédés d'utilisation
|
CN101842116A
(zh)
|
2007-08-28 |
2010-09-22 |
比奥根艾迪克Ma公司 |
结合igf-1r多个表位的组合物
|
EP2033657A1
(fr)
|
2007-09-04 |
2009-03-11 |
Trion Pharma Gmbh |
Application d'anticorps intra-opératoire trifonctionnelle pour la prophylaxie de la dissémination des cellules cancérigènes intrapéritonéales
|
US20100226925A1
(en)
|
2007-09-14 |
2010-09-09 |
Amgen Inc. |
Homogeneous Antibody Populations
|
MX2010003450A
(es)
|
2007-09-26 |
2010-04-27 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo modificada.
|
ES2667729T3
(es)
|
2007-09-26 |
2018-05-14 |
Ucb Biopharma Sprl |
Fusiones de anticuerpos con doble especificidad
|
EP3127921A1
(fr)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Procédé de modification d'un anticorps par point isoélectrique par substitution d'acide aminé dans cdr
|
HUE024903T2
(en)
|
2007-12-26 |
2016-02-29 |
Xencor Inc |
FC variants with modified binding to FCRN
|
SI2235064T1
(sl)
|
2008-01-07 |
2016-04-29 |
Amgen Inc. |
Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
|
WO2009106096A1
(fr)
|
2008-02-27 |
2009-09-03 |
Fresenius Biotech Gmbh |
Traitement de tumeurs résistantes par des anticorps trifonctionnels
|
WO2009126944A1
(fr)
|
2008-04-11 |
2009-10-15 |
Trubion Pharmaceuticals, Inc. |
Produits d’immunothérapie de cd37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
|
CA2723197C
(fr)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Procede et compositions pour preparer des anticorps et des derives d'anticorps avec une fucosylation centrale reduite
|
JP2011523853A
(ja)
|
2008-06-03 |
2011-08-25 |
アボット・ラボラトリーズ |
二重可変ドメイン免疫グロブリン及びその使用
|
WO2010028796A1
(fr)
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Anticorps hexavalents trispécifiques
|
US20170247470A9
(en)
|
2008-09-17 |
2017-08-31 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
CN102292353B
(zh)
|
2008-09-17 |
2015-04-29 |
Xencor公司 |
用于治疗ige介导的疾患的新组合物和方法
|
BRPI0919382A2
(pt)
|
2008-09-26 |
2016-01-05 |
Roche Glycart Ag |
anticorpos bi-específicos anti-egfr/anti-igf-1r
|
PL2352763T5
(pl)
|
2008-10-01 |
2023-01-30 |
Amgen Research (Munich) Gmbh |
Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
|
MX338038B
(es)
|
2008-10-01 |
2016-03-30 |
Amgen Res Munich Gmbh |
Anticuerpo de una sola cadena bis-especifico de pscaxcd3, cd19xcd3, c-metxcd3, endosialinaxcd3, epcamxcd3, igf-1rxcd3 o fapalfaxcd3 de especies cruzadas.
|
US10981998B2
(en)
|
2008-10-01 |
2021-04-20 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
CA2738565C
(fr)
|
2008-10-01 |
2023-10-10 |
Micromet Ag |
Anticorps monocatenaire bispecifique psmaxcd3, specifique d'especes croisees
|
JP2012504970A
(ja)
|
2008-10-10 |
2012-03-01 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Tcr複合体免疫治療
|
BRPI0921687A8
(pt)
|
2008-11-03 |
2022-11-08 |
Syntarga Bv |
Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
|
CN102369291A
(zh)
|
2009-01-23 |
2012-03-07 |
比奥根艾迪克Ma公司 |
效应子功能降低的稳定Fc多肽及使用方法
|
RU2011140498A
(ru)
|
2009-03-06 |
2013-04-20 |
Дженентек, Инк. |
Препарат антител
|
EP2233500A1
(fr)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Variantes Fc optimisées
|
EP2414391B1
(fr)
|
2009-04-02 |
2018-11-28 |
Roche Glycart AG |
Anticorps multispécifiques renfermant des anticorps complets et des fragments fab monocaténaires
|
JP5612663B2
(ja)
|
2009-04-07 |
2014-10-22 |
ロシュ グリクアート アクチェンゲゼルシャフト |
二重特異性抗ErbB−1/抗c−Met抗体
|
JP5587975B2
(ja)
|
2009-04-07 |
2014-09-10 |
ロシュ グリクアート アクチェンゲゼルシャフト |
二重特異的抗−ErbB−3/抗−c−Met抗体
|
WO2010115589A1
(fr)
|
2009-04-07 |
2010-10-14 |
Roche Glycart Ag |
Anticorps trivalents bispécifiques
|
EP2241576A1
(fr)
|
2009-04-17 |
2010-10-20 |
Trion Pharma Gmbh |
Utilisation des anticorps bispécifiques trifonctionnels pour le traitement des tumeurs associées aux cellules souches de cancer CD133+/EpCAM+
|
AU2010252284A1
(en)
|
2009-05-27 |
2011-11-17 |
F. Hoffmann-La Roche Ag |
Tri- or tetraspecific antibodies
|
AU2010265949B2
(en)
|
2009-06-26 |
2016-05-05 |
I2 Pharmaceuticals, Inc. |
Expression of surrogate light chains
|
KR101747103B1
(ko)
|
2009-06-26 |
2017-06-14 |
리제너론 파마슈티칼스 인코포레이티드 |
천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
|
CA2766166A1
(fr)
|
2009-07-08 |
2011-01-13 |
Amgen Inc. |
Conception de molecules fc d'anticorps exemptes d'agregation et stable par ingenierie de l'interface du domaine ch3
|
WO2011028952A1
(fr)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
|
DE102009045006A1
(de)
|
2009-09-25 |
2011-04-14 |
Technische Universität Dresden |
Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
|
CN107227335A
(zh)
|
2009-10-27 |
2017-10-03 |
安进研发(慕尼黑)股份有限公司 |
用于施用CD19xCD3双特异性抗体的给药方案
|
ES2688978T3
(es)
|
2009-11-23 |
2018-11-07 |
Amgen Inc. |
Anticuerpo monomérico Fc
|
EP2504028A4
(fr)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
Inhibition simultanée de pd-l1/pd-l2
|
SI2506871T1
(sl)
|
2009-11-30 |
2016-12-30 |
Janssen Biotech, Inc. |
Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami
|
AU2010336277B2
(en)
|
2009-12-25 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide modification method for purifying polypeptide multimers
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
EP2519544A1
(fr)
|
2009-12-29 |
2012-11-07 |
Emergent Product Development Seattle, LLC |
Hétérodimères polypeptidiques et leurs utilisations
|
US20110189178A1
(en)
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
CA2794708C
(fr)
|
2010-03-29 |
2021-11-16 |
Zymeworks Inc. |
Anticorps presentant une fonction effectrice amelioree ou supprimee
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
跨物種專一性之PSMAxCD3雙專一性單鏈抗體
|
EA201201435A1
(ru)
|
2010-04-20 |
2013-04-30 |
Генмаб А/С |
ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
|
MX346731B
(es)
|
2010-04-23 |
2017-03-30 |
Genentech Inc * |
Producción de proteínas heteromultiméricas.
|
EP2569337A1
(fr)
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Protéines hétérodimériques et leurs procédés de production et de purification
|
EP3613774A1
(fr)
|
2010-06-09 |
2020-02-26 |
Genmab A/S |
Anticorps diriges contre le cd38 humain
|
CA2802344C
(fr)
|
2010-06-18 |
2023-06-13 |
The Brigham And Women's Hospital, Inc. |
Anticorps di-specifiques anti-tim-3 et pd-1 pour immunotherapie dans des etats pathologiques immuns chroniques
|
DK3029066T3
(da)
|
2010-07-29 |
2019-05-20 |
Xencor Inc |
Antistoffer med modificerede isoelektriske punkter
|
CN103154025B
(zh)
|
2010-08-02 |
2015-07-01 |
宏观基因有限公司 |
共价双抗体及其用途
|
WO2012032080A1
(fr)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Fc humain stabilisé
|
MX352929B
(es)
|
2010-11-05 |
2017-12-13 |
Zymeworks Inc |
DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
|
US8637024B2
(en)
|
2010-11-12 |
2014-01-28 |
The Rockefeller University |
Fusion antibodies for HIV therapy
|
DK3489255T3
(da)
|
2011-02-10 |
2021-08-23 |
Roche Glycart Ag |
Muterede interleukin-2-polypeptider
|
US9499605B2
(en)
|
2011-03-03 |
2016-11-22 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
WO2012125495A2
(fr)
|
2011-03-11 |
2012-09-20 |
Amgen Inc. |
Procédé d'analyse mutationnelle corrélée pour améliorer des anticorps thérapeutiques
|
JP5972915B2
(ja)
|
2011-03-16 |
2016-08-17 |
アムジエン・インコーポレーテツド |
Fc変異体
|
EP2688909A2
(fr)
|
2011-03-25 |
2014-01-29 |
Glenmark Pharmaceuticals S.A. |
Immunoglobulines hétéro-dimériques
|
TWI671315B
(zh)
|
2011-03-28 |
2019-09-11 |
法商賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
MX336740B
(es)
|
2011-03-29 |
2016-01-29 |
Roche Glycart Ag |
Variantes de fragmento cristalizable (fc) de los anticuerpos.
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
SI2714733T1
(sl)
|
2011-05-21 |
2019-06-28 |
Macrogenics, Inc. |
CD3-vezavne molekule sposobne vezave na humani ali ne-humani CD3
|
JP2014517846A
(ja)
|
2011-05-25 |
2014-07-24 |
メルク・シャープ・アンド・ドーム・コーポレーション |
改善された特性を有するFc含有ポリペプチドの製造方法
|
EP2729488A4
(fr)
|
2011-07-06 |
2015-01-14 |
Medimmune Llc |
Procédé de préparation de polypeptides multimères
|
EP2736928B1
(fr)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Proteines "sur"-liantes dirigees contre erbb3
|
EP2740793B1
(fr)
|
2011-08-04 |
2017-11-29 |
Toray Industries, Inc. |
Composition de médicament pour traitement et/ou prévention du cancer
|
WO2013022855A1
(fr)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Anticorps avec points isoélectriques modifiés et immunofiltration
|
ES2682254T3
(es)
|
2011-08-18 |
2018-09-19 |
Affinity Biosciences Pty Ltd |
Polipéptidos solubles
|
PE20141521A1
(es)
|
2011-08-23 |
2014-10-25 |
Roche Glycart Ag |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
MX2014002289A
(es)
|
2011-08-26 |
2015-03-20 |
Merrimack Pharmaceuticals Inc |
Anticuerpos fc especificos en tandem.
|
EP3939996A1
(fr)
|
2011-09-30 |
2022-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
AU2012323287B2
(en)
|
2011-10-10 |
2018-02-01 |
Xencor, Inc. |
A method for purifying antibodies
|
CA2850572A1
(fr)
|
2011-10-20 |
2013-04-25 |
Esbatech, A Novartis Company Llc |
Anticorps stable se liant a de multiples antigenes
|
JP6184965B2
(ja)
*
|
2011-10-28 |
2017-08-23 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
ポリペプチド構築物およびその使用
|
KR102398736B1
(ko)
|
2011-10-31 |
2022-05-16 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
DK2773671T3
(da)
|
2011-11-04 |
2021-11-15 |
Zymeworks Inc |
Udformning af stabilt heterodimert antistof med mutationer i fc-domænet
|
CN103906533A
(zh)
|
2011-11-07 |
2014-07-02 |
米迪缪尼有限公司 |
多特异性和多价结合蛋白及其用途
|
WO2013096828A1
(fr)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Protéines substitutives de liaison
|
TW202015731A
(zh)
|
2012-02-24 |
2020-05-01 |
日商中外製藥股份有限公司 |
經FcγRIIB促進抗原消失之抗原結合分子
|
NZ772318A
(en)
|
2012-04-20 |
2023-06-30 |
Merus Nv |
Methods and means for the production of ig-like molecules
|
DK2844667T3
(en)
|
2012-04-30 |
2018-07-30 |
Biocon Ltd |
Targeted / immunomodulatory fusion proteins and methods for their preparation
|
US20150353630A1
(en)
|
2012-05-30 |
2015-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
WO2014004586A1
(fr)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Processus et procédés pour la fabrication efficace d'anticorps asymétriques hautement purs dans des cellules de mammifère
|
KR20150036606A
(ko)
|
2012-07-13 |
2015-04-07 |
자임워크스 인코포레이티드 |
항-cd3 구조체를 포함하는 이중특이적 비대칭 이형이합체
|
AU2013293092A1
(en)
|
2012-07-23 |
2015-02-26 |
Zymeworks Inc. |
Immunoglobulin constructs comprising selective pairing of the light and heavy chains
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
EP2900696A1
(fr)
|
2012-09-25 |
2015-08-05 |
Glenmark Pharmaceuticals S.A. |
Purification d'immunoglobulines hétérodimères
|
JP6571527B2
(ja)
|
2012-11-21 |
2019-09-04 |
ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドWuhan Yzy Biopharma Co., Ltd. |
二重特異性抗体
|
DK2927321T3
(da)
|
2012-11-27 |
2021-03-15 |
Univ Ajou Ind Academic Coop Found |
Ch3-domæne-variantpar der inducerer dannelse af heterodimer af tungkæde konstant region af antistof ved høj effektivitet, fremgangsmåde til fremstilling af samme, og anvendelse deraf
|
WO2014100490A1
(fr)
|
2012-12-19 |
2014-06-26 |
Adimab, Llc |
Analogues d'anticorps multivalents, et leurs procédés de préparation et d'utilisation
|
US10968276B2
(en)
*
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US9701759B2
(en)
*
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
WO2014110601A1
(fr)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Nouvelles protéines hétérodimères
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US20140271462A1
(en)
|
2013-03-13 |
2014-09-18 |
Imaginab, Inc. |
Antigen binding constructs to cd8
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
EP3587448B1
(fr)
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Protéines hétérodimériques
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
EP3421495A3
(fr)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation de cellules t avec des anticorps bispécifiques et des fusions fc
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014209804A1
(fr)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Anticorps bispécifiques
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
KR102564207B1
(ko)
|
2013-08-08 |
2023-08-10 |
싸이튠 파마 |
Il―15 및 il―15r 알파 스시 도메인 기반 모듈로카인
|
EP2839842A1
(fr)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
|
AU2014343636A1
(en)
|
2013-11-04 |
2016-06-02 |
Glenmark Pharmaceuticals S.A. |
Production of T cell retargeting hetero-dimeric immunoglobulins
|
AU2014364593A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody
|
EP3083687A2
(fr)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Polythérapie comprenant des agonistes se liant à ox40 et des antagonistes se liant à l'axe pd-1
|
RS60443B1
(sr)
|
2013-12-17 |
2020-07-31 |
Genentech Inc |
Anti-cd3 antitela i postupci upotrebe
|
RU2016129959A
(ru)
|
2013-12-30 |
2018-02-02 |
Эпимаб Биотерепьютикс Инк. |
Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
|
CA2935599A1
(fr)
|
2014-01-08 |
2015-07-16 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Proteine il-15 heterodimerique et ses utilisations
|
US9603927B2
(en)
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
CR20160506A
(es)
|
2014-03-28 |
2017-03-10 |
Xencor Inc |
Anticuerpos biespecíficos que se unen a cd38 y cd3
|
RU2577226C2
(ru)
|
2014-04-10 |
2016-03-10 |
Общество с ограниченной ответственностью, "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") |
Способ получения биспецифических антител против cd3*cd19 формата флексибоди в клетках млекопитающих
|
WO2015168379A2
(fr)
|
2014-04-30 |
2015-11-05 |
President And Fellows Of Harvard College |
Dispositifs de vaccin combiné et procédés de destruction de cellules cancéreuses
|
US10647768B2
(en)
|
2014-05-29 |
2020-05-12 |
Macrogenics, Inc. |
Multi-chain polypeptide-containing tri-specific binding molecules
|
AU2015292326A1
(en)
|
2014-07-24 |
2017-02-23 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
CN112410363A
(zh)
|
2014-08-19 |
2021-02-26 |
诺华股份有限公司 |
抗cd123嵌合抗原受体(car)用于癌症治疗
|
EP3191187B1
(fr)
|
2014-09-09 |
2021-07-28 |
Janssen Biotech, Inc. |
Polythérapies avec des anticorps anti-cd38
|
MA40894A
(fr)
|
2014-11-04 |
2017-09-12 |
Glenmark Pharmaceuticals Sa |
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
|
DK3221355T3
(da)
|
2014-11-20 |
2020-12-07 |
Hoffmann La Roche |
Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
|
US10259887B2
(en)
*
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
US20160176969A1
(en)
|
2014-11-26 |
2016-06-23 |
Xencor, Inc. |
Heterodimeric antibodies including binding to cd8
|
DK3223845T3
(da)
|
2014-11-26 |
2021-08-16 |
Xencor Inc |
Heterodimere antistoffer, der binder cd3 og cd20
|
CA2968878A1
(fr)
*
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Anticorps heterodimeriques se liant aux antigenes cd3 et cd38
|
EP3237449A2
(fr)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Anticorps trispécifiques
|
SI3623386T1
(sl)
|
2015-01-08 |
2022-09-30 |
BioNTech SE |
Agonistična TNF receptor vezavna sredstva
|
CN107614522A
(zh)
|
2015-01-14 |
2018-01-19 |
指南针制药有限责任公司 |
多特异性免疫调节性抗原结合构建体
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
AU2016262368B2
(en)
|
2015-05-08 |
2019-05-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
US20160376373A1
(en)
|
2015-06-24 |
2016-12-29 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
LT3328419T
(lt)
|
2015-07-30 |
2021-11-10 |
Macrogenics, Inc. |
Pd-1 surišančios molekulės ir jų panaudojimo būdai
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
SI3394103T1
(sl)
|
2015-12-22 |
2023-10-30 |
Regeneron Pharmaceuticals, Inc. |
Kombinacija protiteles proti-PD-1 in bispecifičnih protiteles proti-CD20/proti-CD3 za zdravljenje raka
|
WO2017210443A1
(fr)
|
2016-06-01 |
2017-12-07 |
Xencor, Inc. |
Anticorps bispécifiques qui lient cd123 et cd3
|
EP3464370A1
(fr)
|
2016-06-01 |
2019-04-10 |
Xencor, Inc. |
Anticorps bispécifiques qui se lient à cd20 et cd3 destinés à être utilisés dans le traitement d'un lymphome
|
EP3252078A1
(fr)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Anticorps de type ii contre cd20 et anticorps bispecifique contre cd20/cd3 pour traitement de cancer
|
JP2019517539A
(ja)
|
2016-06-07 |
2019-06-24 |
マクロジェニクス,インコーポレーテッド |
併用療法
|
WO2017218707A2
(fr)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Anticorps inhibiteurs de points de contrôle bispécifiques
|
CN116063545A
(zh)
|
2016-06-28 |
2023-05-05 |
Xencor股份有限公司 |
结合生长抑素受体2的异源二聚抗体
|
WO2018017863A1
(fr)
|
2016-07-21 |
2018-01-25 |
Dcb-Usa Llc |
Fragments fab liant l'antigène modifiés et molécules liant l'antigène les comprenant
|
BR112019003866A2
(pt)
|
2016-08-29 |
2019-07-16 |
Psioxus Therapeutics Ltd |
adenovírus estimulado com fragmento de mab biespecífico com redirecionamento de células t (bite)
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EP3526241A1
(fr)
|
2016-10-14 |
2019-08-21 |
Xencor, Inc. |
Protéines de fusion fc hétérodimères il15/il15r
|
WO2019050521A1
(fr)
|
2017-09-07 |
2019-03-14 |
Macrogenics, Inc. |
Schémas posologiques de diacorps bispécifiques cd123 x cd3 dans le traitement de malignités hématologiques
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US20210102002A1
(en)
|
2019-08-06 |
2021-04-08 |
Xencor, Inc. |
HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES
|